Which has stronger earnings and valuation, GEHC or SNN?

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GE HealthCare Technologies $20.63B 1.44 $2.08B $4.18 15.62 Smith & Nephew SNATS $6.16B 2.13 $625M N/A N/A

Does the media favor GEHC or SNN?

In the previous week, GE HealthCare Technologies had 8 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 12 mentions for GE HealthCare Technologies and 4 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 0.78 beat Smith & Nephew SNATS's score of 0.76 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PHG or SNN?

Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential downside of 0.49%. Given Smith & Nephew SNATS's stronger consensus rating and higher possible upside, analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Smith & Nephew SNATS 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17

Which has better earnings and valuation, PHG or SNN?

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $20.17B 1.33 $1.01B $1.17 23.36 Smith & Nephew SNATS $6.16B 2.13 $625M N/A N/A

Does the media favor PHG or SNN?

In the previous week, Smith & Nephew SNATS had 2 more articles in the media than Koninklijke Philips. MarketBeat recorded 4 mentions for Smith & Nephew SNATS and 2 mentions for Koninklijke Philips. Smith & Nephew SNATS's average media sentiment score of 0.76 beat Koninklijke Philips' score of 0.00 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SNN or ZBH?

Zimmer Biomet has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.13 $625M N/A N/A Zimmer Biomet $8.23B 2.21 $705.20M $3.85 24.44

Does the media refer more to SNN or ZBH?

In the previous week, Zimmer Biomet had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 11 mentions for Zimmer Biomet and 4 mentions for Smith & Nephew SNATS. Zimmer Biomet's average media sentiment score of 1.16 beat Smith & Nephew SNATS's score of 0.76 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, SNN or SOLV?

Solventum has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.13 $625M N/A N/A Solventum $8.33B 1.61 $1.56B $8.16 9.50

Does the media refer more to SNN or SOLV?

In the previous week, Solventum had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 9 mentions for Solventum and 4 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 1.32 beat Smith & Nephew SNATS's score of 0.76 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PEN or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Penumbra. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.45B 8.62 $177.69M $4.34 73.41 Smith & Nephew SNATS $6.16B 2.13 $625M N/A N/A

Does the media prefer PEN or SNN?

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than Penumbra. MarketBeat recorded 4 mentions for Smith & Nephew SNATS and 3 mentions for Penumbra. Smith & Nephew SNATS's average media sentiment score of 0.76 beat Penumbra's score of 0.00 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Smith & Nephew SNATS (SNN) Competitors

$31.08 +0.38 (+1.22%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$31.08 +0.01 (+0.03%)

As of 07/13/2026 04:10 PM Eastern

Compare

SNN vs. GEHC, PHG, ZBH, SOLV, and PEN

Should you buy Smith & Nephew SNATS stock or one of its competitors? MarketBeat compares Smith & Nephew SNATS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smith & Nephew SNATS include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), and Penumbra (PEN). These companies are all part of the "medical equipment" industry.

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, GE HealthCare Technologies had 8 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 12 mentions for GE HealthCare Technologies and 4 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 0.78 beat Smith & Nephew SNATS's score of 0.76 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.0%. GE HealthCare Technologies pays out 3.3% of its earnings in the form of a dividend. GE HealthCare Technologies has increased its dividend for 1 consecutive years.

GE HealthCare Technologies has a net margin of 9.10% compared to Smith & Nephew SNATS's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.46% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Smith & Nephew SNATS	N/A	N/A	N/A

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.44	$2.08B	$4.18	15.62
Smith & Nephew SNATS	$6.16B	2.13	$625M	N/A	N/A

GE HealthCare Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

GE HealthCare Technologies presently has a consensus target price of $79.48, suggesting a potential upside of 21.69%. Smith & Nephew SNATS has a consensus target price of $30.93, suggesting a potential downside of 0.49%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe GE HealthCare Technologies is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.50
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

GE HealthCare Technologies beats Smith & Nephew SNATS on 13 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Koninklijke Philips has a net margin of 5.49% compared to Smith & Nephew SNATS's net margin of 0.00%. Koninklijke Philips' return on equity of 13.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Smith & Nephew SNATS	N/A	N/A	N/A

Koninklijke Philips has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

13.7% of Koninklijke Philips shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential downside of 0.49%. Given Smith & Nephew SNATS's stronger consensus rating and higher possible upside, analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.33	$1.01B	$1.17	23.36
Smith & Nephew SNATS	$6.16B	2.13	$625M	N/A	N/A

Koninklijke Philips pays an annual dividend of $0.84 per share and has a dividend yield of 3.1%. Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.0%. Koninklijke Philips pays out 71.8% of its earnings in the form of a dividend.

In the previous week, Smith & Nephew SNATS had 2 more articles in the media than Koninklijke Philips. MarketBeat recorded 4 mentions for Smith & Nephew SNATS and 2 mentions for Koninklijke Philips. Smith & Nephew SNATS's average media sentiment score of 0.76 beat Koninklijke Philips' score of 0.00 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Smith & Nephew SNATS beats Koninklijke Philips on 9 of the 16 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Smith & Nephew SNATS (NYSE:SNN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.0%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.0%. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend.

Zimmer Biomet has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.13	$625M	N/A	N/A
Zimmer Biomet	$8.23B	2.21	$705.20M	$3.85	24.44

Smith & Nephew SNATS has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Smith & Nephew SNATS presently has a consensus price target of $30.93, indicating a potential downside of 0.49%. Zimmer Biomet has a consensus price target of $102.33, indicating a potential upside of 8.76%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts clearly believe Zimmer Biomet is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Zimmer Biomet	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Zimmer Biomet had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 11 mentions for Zimmer Biomet and 4 mentions for Smith & Nephew SNATS. Zimmer Biomet's average media sentiment score of 1.16 beat Smith & Nephew SNATS's score of 0.76 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has a net margin of 9.05% compared to Smith & Nephew SNATS's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Zimmer Biomet	9.05%	13.24%	7.28%

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Zimmer Biomet beats Smith & Nephew SNATS on 14 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Solventum?

Smith & Nephew SNATS (NYSE:SNN) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Solventum has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.13	$625M	N/A	N/A
Solventum	$8.33B	1.61	$1.56B	$8.16	9.50

Smith & Nephew SNATS currently has a consensus target price of $30.93, indicating a potential downside of 0.49%. Solventum has a consensus target price of $83.67, indicating a potential upside of 7.98%. Given Solventum's stronger consensus rating and higher probable upside, analysts plainly believe Solventum is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43

Smith & Nephew SNATS has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Solventum has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Solventum had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 9 mentions for Solventum and 4 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 1.32 beat Smith & Nephew SNATS's score of 0.76 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a net margin of 17.33% compared to Smith & Nephew SNATS's net margin of 0.00%. Solventum's return on equity of 23.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Solventum	17.33%	23.51%	7.63%

Summary

Solventum beats Smith & Nephew SNATS on 11 of the 14 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Penumbra?

Penumbra (NYSE:PEN) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Penumbra has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than Penumbra. MarketBeat recorded 4 mentions for Smith & Nephew SNATS and 3 mentions for Penumbra. Smith & Nephew SNATS's average media sentiment score of 0.76 beat Penumbra's score of 0.00 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra currently has a consensus price target of $360.33, indicating a potential upside of 13.09%. Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential downside of 0.49%. Given Penumbra's higher probable upside, equities analysts clearly believe Penumbra is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Smith & Nephew SNATS has higher revenue and earnings than Penumbra.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.45B	8.62	$177.69M	$4.34	73.41
Smith & Nephew SNATS	$6.16B	2.13	$625M	N/A	N/A

Penumbra has a net margin of 11.76% compared to Smith & Nephew SNATS's net margin of 0.00%. Penumbra's return on equity of 10.87% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Smith & Nephew SNATS	N/A	N/A	N/A

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Penumbra beats Smith & Nephew SNATS on 9 of the 14 factors compared between the two stocks.

Get Smith & Nephew SNATS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNN vs. The Competition

Export

Metric	Smith & Nephew SNATS	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$12.97B	$8.82B	$7.05B	$23.46B
Dividend Yield	3.04%	2.54%	2.68%	4.02%
P/E Ratio	N/A	16.09	27.11	31.08
Price / Sales	2.13	7.04	587.92	19.77
Price / Cash	8.95	18.40	29.22	18.64
Price / Book	2.50	3.57	10.75	4.77
Net Income	$625M	$228.19M	$3.58B	$1.06B
7 Day Performance	1.99%	-2.31%	-2.06%	-0.23%
1 Month Performance	1.82%	-0.62%	3.32%	-0.11%
1 Year Performance	3.40%	-2.73%	26.35%	16.46%

Smith & Nephew SNATS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNN Smith & Nephew SNATS	2.0173 of 5 stars	$31.08 +1.2%	$30.93 -0.5%	+2.6%	$12.97B	$6.16B	N/A	16,988	News Coverage
GEHC GE HealthCare Technologies	4.9399 of 5 stars	$64.94 +0.2%	$80.20 +23.5%	-13.1%	$29.55B	$20.98B	15.54	54,000	Analyst Forecast
PHG Koninklijke Philips	1.87 of 5 stars	$28.14 -0.1%	N/A	+13.8%	$27.67B	$17.64B	24.12	65,340
ZBH Zimmer Biomet	3.5278 of 5 stars	$89.69 -0.1%	$102.70 +14.5%	+0.2%	$17.36B	$8.23B	23.31	17,000	Positive News
SOLV Solventum	3.9393 of 5 stars	$75.93 -2.6%	$83.73 +10.3%	+5.1%	$13.14B	$8.33B	9.30	20,000	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SNN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew SNATS (SNN) Competitors

SNN vs. GEHC, PHG, ZBH, SOLV, and PEN

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Summary

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Summary

How does Smith & Nephew SNATS compare to Solventum?

Summary

How does Smith & Nephew SNATS compare to Penumbra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew SNATS (SNN) Competitors

SNN vs. GEHC, PHG, ZBH, SOLV, and PEN

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Do insiders and institutionals hold more shares of GEHC or SNN?

Does the media favor GEHC or SNN?

Is GEHC or SNN a better dividend stock?

Is GEHC or SNN more profitable?

Which has stronger earnings and valuation, GEHC or SNN?

Which has more volatility and risk, GEHC or SNN?

Do analysts rate GEHC or SNN?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Is PHG or SNN more profitable?

Which has more risk and volatility, PHG or SNN?

Do institutionals & insiders believe in PHG or SNN?

Do analysts prefer PHG or SNN?

Which has better earnings and valuation, PHG or SNN?

Is PHG or SNN a better dividend stock?

Does the media favor PHG or SNN?

Summary

How does Smith & Nephew SNATS compare to Zimmer Biomet?

Is SNN or ZBH a better dividend stock?

Which has higher earnings and valuation, SNN or ZBH?

Which has more risk and volatility, SNN or ZBH?

Do analysts prefer SNN or ZBH?

Does the media refer more to SNN or ZBH?

Is SNN or ZBH more profitable?

Do insiders & institutionals believe in SNN or ZBH?

Summary

How does Smith & Nephew SNATS compare to Solventum?

Which has preferable earnings & valuation, SNN or SOLV?

Do analysts prefer SNN or SOLV?

Which has more risk and volatility, SNN or SOLV?

Do institutionals & insiders hold more shares of SNN or SOLV?

Does the media refer more to SNN or SOLV?

Is SNN or SOLV more profitable?

Summary

How does Smith & Nephew SNATS compare to Penumbra?

Which has more volatility & risk, PEN or SNN?

Does the media prefer PEN or SNN?

Do analysts recommend PEN or SNN?

Which has better earnings & valuation, PEN or SNN?

Is PEN or SNN more profitable?

Do insiders & institutionals believe in PEN or SNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools